President Donald Trump's second term in office has been challenging for investors, at least so far. Trump imposed sweeping ...

Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Behind Lilly's decline ...

Eli Lilly and Purdue University expand their partnership with a $250 million investment to advance pharmaceutical innovation ...

The investment over the next eight years could be the largest ever industry-academic agreement of its kind in the U.S., the ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...

Eli Lilly is investing more in its home state of Indiana, pumping up to $250 million more into an existing collaboration with ...

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).

Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio.

U.S. equities advanced at midday as President Donald Trump announced a new trade deal with the United Kingdom. The Dow Jones ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...